Contraceptives Drugs And Devices Market - Choice to Conceive, Not Concede | Top Players Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., Cooper Surgical, Inc., Allergan plc, Cipla Limited, Merck & Co. Inc.

Contraceptives are birth spacing products that aid in avoiding unwanted/ unplanned pregnancy. There are five widely used contraceptive methods namely barrier method, hormonal method, emergency contraception, intrauterine method, and sterilization. Women can opt for wide range of contraceptive options such as vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects. The use of contraceptives can avoid 60% of maternal deaths and 57% of child deaths worldwide, as opined by the World Health Organization (WHO) in 2014. Therefore, various family planning initiatives have been introduced across the globe be governmental and non-governmental agencies in order to create awareness about prevention of unplanned pregnancy.

Get Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/365

Market Dynamics

Use of contraceptives is low in emerging economies especially in Africa, according to report ‘Trends in Contraceptive Use Worldwide 2015’, of the United Nations in 2015. Moreover, WHO estimates that around 225 million women in as of 2015, emerging economies who would like to delay their pregnancy are not using any contraception method. The impact of this is realized through the number of abortions carried out each year, with around 21.6 million unsafe abortions reported annually. Around 85% of these are reported in emerging economies in Africa and Asia, as per estimates of WHO (2016). Increasing awareness among the population through government initiatives and increasing accessibility to various contraceptive devices and drugs are expected to propel growth of contraceptive drugs and devices market in the near future.

The demand for advanced contraceptive options such as IUD, injectables, combined oral pills and diaphragms is observed to be high globally. This is owing to growing awareness among the populace, availability of reimbursement and growing demand for long term contraceptive methods.

Market Taxonomy

This report segments the global contraceptives drugs and devices market on the basis of product type and geography. On the basis of product type, the global contraceptives market is segmented into drug and devices. Drugs are further sub-segmented into oral pills, injectables, and topical contraceptives. The contraceptive devices segment is further sub-segmented into male contraceptives devices and female contraceptives devices. Mentioned below is the detailed segmentation. For comprehensive understanding of market dynamics, the global contraceptives drugs and devices market is analyzed across key geographies namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key features of the study:

- This report provides in-depth analysis of the contraceptives drugs and devices and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year

- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading players

- It profiles leading players in the global contraceptives drugs and devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Reckitt Benckiser Plc, Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., The Female Health Company, Cooper Surgical, Inc., Allergan plc, Cipla Limited, and Merck & Co. Inc.

- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, market expansion, and marketing tactics

- The global contraceptives market report caters to various stakeholders in this industry, including investors, drug and device manufacturers, distributors and suppliers for contraceptives drugs and devices, government organizations, research and consulting firms, new entrants, and financial analysts

- Various strategy matrices used in analyzing the contraceptives drugs and devices market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

Global Contraceptives Drugs And Devices Market, By Product Type:
Oral Contraceptive Pills
Contraceptive Injectables
Topical Contraceptives
Male Contraceptive Devices
- Condoms
Female Contraceptive Devices
- Hormonal
- Copper-T
- Female Condoms
- Contraceptive Diaphragms
- Contraceptive Sponges
- Contraceptive Vaginal Rings
- Intrauterine Devices
- Subdermal Contraceptive Implants
Contraceptive Drugs
Contraceptive Devices

Read summary of report here: https://www.coherentmarketinsights.com/market-insight/contraceptives-drugs-and-devices-market-365

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.